Corvus Pharma (CRVS) Presents New Ciforadenant Preclinical Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 973,100 shares, a growth of 113.6% from the May 15th total of 455,500 shares. Based on an average daily trading volume, of 862,100 shares, […]
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) had its target price lifted by LADENBURG THALM/SH SH from $4.00 to $10.00 in a research report released on Tuesday morning, The Fly reports. A number of other equities analysts also recently commented on CRVS. Mizuho restated a neutral rating and issued a $3.50 target price on shares of […]
31.05.2023 - BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) - Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will .